Vantage Data Points

Datapoint: Cell and gene therapy trials

The above graphic shows the number of gene and cell therapy trials for all products in clinical development or filed for approval, as listed in


For a larger/zoomable version of the image click here 

China's PD(L)-1 players

After Celgene’s return of tislelizumab rights Beigene will be looking for a new ex-China partner. The volume of work Beigene and others are already doing in China suggests the threat to US players of multiple low-cost, Asia-developed drugs.

Image can be enlarged by opening in new tab on Chrome or other browsers.

Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.